Publications
- Overcoming resistance to rituximab in relapsed non-Hodgkin lymphomas by antibody-polymer drug conjugates actively targeted by anti-CD38 daratumumab2020 | First Faculty of Medicine
- Ibrutinib in mantle cell lymphoma: a real-world retrospective multi-center analysis of 77 patients treated in the Czech Republic2023 | First Faculty of Medicine, Faculty of Medicine in Hradec Králové, Third Faculty of Medicine
- Complex genetic and histopathological study of 15 patient-derived xenografts of aggressive lymphomas2022 | First Faculty of Medicine, Second Faculty of Medicine, Faculty of Medicine in Pilsen, Faculty of Physical Education and Sport
- Quantitative In Vivo Monitoring of Hypoxia and Vascularization of Patient-Derived Murine Xenografts of Mantle Cell Lymphoma Using Photoacoustic and Ultrasound Imaging2021 | First Faculty of Medicine, Faculty of Medicine in Pilsen
- Cytarabine nanotherapeutics with increased stability and enhanced lymphoma uptake for tailored highly effective therapy of mantle cell lymphoma2021 | First Faculty of Medicine
- CD31/PECAM-1 impacts engraftment, growth and spread of mantle cell lymphoma cells and positively correlates with extramedullary involvement2021 | First Faculty of Medicine
- Dimethyl fumarate induces ferroptosis and impairs NF-kappa B/STAT3 signaling in DLBCL2021 | First Faculty of Medicine
- Anti-CD38 Therapy with Daratumumab for Relapsed/Refractory CD20-Negative Diffuse Large B-Cell Lymphoma2020 | First Faculty of Medicine, Second Faculty of Medicine
- Cotargeting of BCL2 with venetoclax and MCL1 with S63845 is synthetically lethal in vivo in relapsed mantle cell lymphoma2019 | First Faculty of Medicine, Second Faculty of Medicine
- Hematopoiesis in patients with mature B-cell malignancies is deregulated even in patients with undetectable bone marrow involvement2017 | First Faculty of Medicine
Loading network view...